<sup id="hyvjk"><menu id="hyvjk"><form id="hyvjk"></form></menu></sup> <dl id="hyvjk"><menu id="hyvjk"></menu></dl>

<dl id="hyvjk"></dl>
<delect id="hyvjk"></delect>

<em id="hyvjk"><ins id="hyvjk"><small id="hyvjk"></small></ins></em>

<sup id="hyvjk"><meter id="hyvjk"></meter></sup><em id="hyvjk"></em>

Overview

China Pharma IP Summit is a serial event dedicated to pharmaceutical IP protection, and so far we have hold 2 sessions in the year of 2016 and 2017. Government agencies, pharmaceutical/biotech companies, law firms/ IP agencies and other IP solution providers have been invited to attend and we discussed lots of hot issues. Meanwhile, the event has been a good networking platform for industry experts both from local China and abroad.

2017 is a year of great significance in China pharmaceutical industry. On May 2017, China Food and Drug Administration (CFDA) issued Policy Notice No. 55, entitled “Policies Relevant to the Protection of the Rights and Interests of Innovators for the Encouragement of Innovation in Drugs and Medical Devices”. On October 2017, the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation was officially issued, clearly putting forward the establishing patent linkage system, launching pilot program on drug patent extension, completing data protection and implementing list of marketed drugs. At the moment, China is conducting legislation for patent linkage and patent extension, which draws lots of attention.

In terms of intellectual property judicial, on Feb 2018, General Office of the CPC and General Office of the State Council issued Strengthening the Intellectual Property Judicial Reform and Innovation, which is the first guiding document regarding to intellectual property judicial. Pharmaceutical is heavily relied on IP protection, and we predict the guiding document will have influence on pharmaceutical IP litigation in China.

Based on the background, we are glad to inform that 3rd China Pharma IP Summit 2018 will be hold on 24th -26th October in Beijing, providing a platform to discuss updated policies and hot issues.

Through the event, you will have chance to:

1. Follow the latest development of patent linkage and patent term extension reform in China

2. Understand the differences and updated requirements of examination standards, patent invalidation, patent litigation in China, US, EU, Japan and other region.

3. Learn IP management experience from pharmaceutical company

4. Meet you clients/partners fact to face and interact with industry peers

The participants are mainly from pharma/biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, research institutes. If you would like to attend or sponsor our summit, please feel free to call / email us to reserve your seats ASAP!

Thanks again for your attention and looking forward to your participation!



Agenda:

Day1:24, Oct. 2018


Day1 Morning: Policies Updated in China


0730 Registration


0840


Opening Remarks

Qingkui Zhang, Director, Pharmaceutical IP Research Committee of Chinese Pharmaceutical Association



0900


Pharmaceutical IP Index and Evaluation of Pre-Revenue Pharmaceutical Innovators Going Public in Hong Kong

Pharmaceutical companies developing new drugs in clinical trials can now file IPO in Hong Kong without any revenue if they have strong long term patent rights. Tony Chen (Jones Day) and Matthew Chervenak (General Biologic) will introduce a Pharmaceutical IP Index to measure true economic exclusivity of innovative drugs by taking into account patent term, patent strength, regulatory data protection and other factors. They will demonstrate how π Value will help the market assess the long term IP value of innovative pharmaceutical companies in China and explain the potential impact of pharmaceutical IP reform in China on innovation.

Tony Chen, Partner, Jones Day

Matthew Chervenak, Founder and CEO, General Biologic (GBI)



0930

Panel Discussion: Pharmaceutical Innovation and IP Protection in China

China is exploring to establish patent linkage and patent term extension system. The industry is waiting for more detailed implementation rules. We will invite experts to share the updates and developments.

Moderator:

Yongshun Cheng, Director, Beijing Intellectual Property Institute

Panelists:

Qingkui Zhang, Director, Pharmaceutical IP Research Committee of Chinese Pharmaceutical Association

Tony Chen, Partner, Jones Day

Taoxi Lin, IP Director, HEC Group

Elaine Li, Partner, ADVANCE CHINA IP LAW OFFICE



1040
Coffee Break


1110

Projecting Characteristics and Trends of Pharma Patent Invalidation in China under the New Patent Linkage System

Juhua Luo, Deputy Director of Chemical Patent Department, CCPIT Patent and Trademark Law Office

1150

The Patent Linkage for Pharmaceuticals -A Worldwide Perspective

Yehudah Livneh, Strategic IP Consultant;

Former General Patent Counsel and VP Corporate IP and Legislative Affairs, Teva Pharmaceuticals



1240 Lunch Buffet


Day 1 Afternoon: Focus on US


1400

Chair Speech

Ningling Wang,Shanghai Office Managing Partner, Finnegan, Henderson, Farabow,Garrett & Dunner, LLP



1405

Strategies to Improve Certainty and Reduce Costs in Paragraph IV Litigation

Shashank Upadhye, Founding Partner, Amin Talati Upadhye, LLP



1440


Business Development of Pharma Companies in the Era of Big Data: Leveraging Patent Information in Strategic Partnership Scouting and Drug Development

Li Miao, IP Consultant, LexisNexis



1515

Coffee Break



1550

Navigating the IP/FDA Exclusivity Waters Recent Developments Affecting The Journey to 505(b)(1), 505(b)(2), ANDA and Biologics Approval in the US

Christopher Griffith, Founding Partner, Green, Griffith & Borg-Breen LLP



1625

Navigating the Safe Harbor Provision of the Hatch-Waxman Act

Alyson Wooten, Counsel, Kilpatrick Townsend & Stockton LLP



1700

Panel Discussion:Strengths and Risks in the Use of Patents to Protect Market Exclusivity in the US

Moderator:

Ningling Wang,Shanghai Office Managing Partner, Finnegan, Henderson, Farabow,Garrett & Dunner, LLP

Panelists:

Janet Xiao, Partner, Morrison & Foerster LLP

Cynthia Lan Martin, Senior Patent Attorney, AstraZeneca

Steven H. Sklar, Member, Leydig, Voit & Mayer

Yieyie Yang, Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP



1800 Cocktail  (Sponsored  by Womble Bond Dickinson (US) LLP


Day2: 25, Oct. 2018


Day2 Morning: Focus on China

0830


Chairman Opening Remark

Chairman: Li Wu, Senior Consultant, AnJie Law Firm



0840

Pharmaceutical High Value Patent Cultivation

Qiujuan Ma, Director for Pharmaceutical, Patent Examination Cooperation Center of SIPO



0920

Pharmaceutical Patent Trial in China

Chi Su, Director of IP Case Guidance Research (Beijing) Base of the Supreme Peoples Court and President of Beijing IP Law Association; First President, Beijing Intellectual Property Court (Retired in Dec. 2017)



1000

Coffee Break

1030

Analyzing and Discussing Pharmaceutical Patent Infringement Litigation Case

HENG DU LAW FIRM



1110

Panel Discussion: Regulatory Data Protection in China

Moderator:

Chen Yang, Senior Counsel, Sidley Austin LLP

Panelists:

Xu Yang, Patent Attorney, BeiGene, Ltd.

Kent Yang, Head Patents China, Novartis Pharmaceuticals (China)

Yue Yang, Director, International Center for Food and Drug Policy and Law,

Shenyang Pharmaceutical University



1145

Panel Discussion: Hot Cases of Pharmaceutical Patent Invalidation in China and Implication

Moderator:

Li Wu, Senior Consultant, AnJie Law Firm

Panelists:

Xiaolan Ren, Director of Chemical Appeal Department, The Patent Reexamination Board of the CNIPA (National Intellectual Property Administration, PRC)

Feng Xu, IP Director for China and Asia, AstraZeneca

Nick Liu, Partner, AnJie Law Firm (Former Senior Judge at Intellectual Property Division of Beijing Higher Peoples Court)



1235 Lunch


Day2 Afternoon: Focus on EU


1400

Chair Speech

Andreas Oser, Partner, Prüfer & Partner



1405

The Latest Developments at EPO (including pertinent case law)

Klaus-Peter D?pfer, Director Biotechnology, Sector Healthcare-Biotechnology-Chemistry, EPO

1440


The Supplementary Protection Certificate in Europe and Potential Modification (including introduction of a manufacturing waiver)

Andreas Oser, Partner, Prüfer & Partner

1515

Coffee Break

1620


Is your invention plausible? The rising importance of the “plausibility” hurdle in life science and pharmaceutical patents”

Hsu Min Chung, Partner, HGF Limited



1625

Secondary Patents - Current Developments And Challenges in Europe

Ute Kilger, Partner, Boehmert & Boehmert

Markus Engelhard, Partner, Boehmert & Boehmert



1700

Panel Discussion: Patent Protection and Enforcement of First, Second or Further Medical Uses of Known Compounds/Pharmaceutical Products in Europe

Moderator:

Andreas Oser, Partner, Prüfer & Partner

Panelists:

Hsu Min Chung, Partner, HGF Limited

Klaus-Peter D?pfer, Director Biotechnology, Sector Healthcare-Biotechnology-Chemistry, EPO

Ute Kilger, Partner, Boehmert & Boehmert

Markus Engelhard, Partner, Boehmert & Boehmert



Day3: 26, Oct. 2018


Day3 Morning: Other Region


0830

Chairman Opening Remark:

Mahendra B. Thakre, General Manager – IPR Legal, Mylan Laboratories Limited



0840

Pharmaceutical Patent Protection and Patent Term Extension Regime in Japan

Koichiro Morihira, Head of Intellectual Property, Astellas Pharma Inc.



0920

Optimizing Overseas Pharma M&A DecisionsBig Data Supported IP Due Diligence

Chieh-Mei Wang, Vice President, ScienbiziP Consulting (Shen Zhen) Co., Ltd.



1000

Coffee Break



1035

The Generic Pharmaceutical in India and Patent Compulsory Licensing System

Mahendra B. Thakre, General Manager – IPR Legal, Mylan Laboratories Limited



1110

US Updates and Effect on Pharmaceutical Companies

Todd Volyn, Associate Patent Counsel, Johnson & Johnson



1145

Conference Closing Remark






 

  Media Partner

奇米网狠狠网